161 related articles for article (PubMed ID: 7876563)
1. Correction of proliferative responses in purine nucleoside phosphorylase (PNP)-deficient T lymphocytes by retroviral-mediated PNP gene transfer and expression.
Nelson DM; Butters KA; Markert ML; Reinsmoen NL; McIvor RS
J Immunol; 1995 Mar; 154(6):3006-14. PubMed ID: 7876563
[TBL] [Abstract][Full Text] [Related]
2. Correction of purine nucleoside phosphorylase deficiency by retroviral-mediated gene transfer in mouse S49 T cell lymphoma: a model for gene therapy of T cell immunodeficiency.
Foresman MD; Nelson DM; McIvor RS
Hum Gene Ther; 1992 Dec; 3(6):625-31. PubMed ID: 1482702
[TBL] [Abstract][Full Text] [Related]
3. Lentivirus gene therapy for purine nucleoside phosphorylase deficiency.
Liao P; Toro A; Min W; Lee S; Roifman CM; Grunebaum E
J Gene Med; 2008 Dec; 10(12):1282-93. PubMed ID: 18924118
[TBL] [Abstract][Full Text] [Related]
4. TAT-mediated intracellular delivery of purine nucleoside phosphorylase corrects its deficiency in mice.
Toro A; Grunebaum E
J Clin Invest; 2006 Oct; 116(10):2717-26. PubMed ID: 16964310
[TBL] [Abstract][Full Text] [Related]
5. Intracellular delivery of purine nucleoside phosphorylase (PNP) fused to protein transduction domain corrects PNP deficiency in vitro.
Toro A; Paiva M; Ackerley C; Grunebaum E
Cell Immunol; 2006 Apr; 240(2):107-15. PubMed ID: 16930574
[TBL] [Abstract][Full Text] [Related]
6. Purine nucleoside phosphorylase deficiency.
Markert ML
Immunodefic Rev; 1991; 3(1):45-81. PubMed ID: 1931007
[TBL] [Abstract][Full Text] [Related]
7. In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells.
Gadi VK; Alexander SD; Kudlow JE; Allan P; Parker WB; Sorscher EJ
Gene Ther; 2000 Oct; 7(20):1738-43. PubMed ID: 11083495
[TBL] [Abstract][Full Text] [Related]
8. Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene.
Hughes BW; Wells AH; Bebok Z; Gadi VK; Garver RI; Parker WB; Sorscher EJ
Cancer Res; 1995 Aug; 55(15):3339-45. PubMed ID: 7614469
[TBL] [Abstract][Full Text] [Related]
9. [Purine nucleoside phosphorylase activity in T-enriched preparations of human peripheral lymphocytes].
Russo M; Pizzella T; Nardiello S; Galanti B
Boll Soc Ital Biol Sper; 1981 May; 57(9):990-2. PubMed ID: 6793048
[TBL] [Abstract][Full Text] [Related]
10. Activation conditions determine susceptibility of murine primary T-lymphocytes to retroviral infection.
Hagani AB; Rivière I; Tan C; Krause A; Sadelain M
J Gene Med; 1999; 1(5):341-51. PubMed ID: 10738551
[TBL] [Abstract][Full Text] [Related]
11. Long-term expression of gene introduction into normal human T-lymphocytes by retroviral-mediated gene transfer.
Fauser AA
J Cell Biochem; 1991 Apr; 45(4):353-8. PubMed ID: 2045429
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of 2-fluoro-2'-deoxyadenosine against tumors that express Escherichia coli purine nucleoside phosphorylase.
Parker WB; Allan PW; Hassan AE; Secrist JA; Sorscher EJ; Waud WR
Cancer Gene Ther; 2003 Jan; 10(1):23-9. PubMed ID: 12489025
[TBL] [Abstract][Full Text] [Related]
13. [Purine nucleoside phosphorylase (PNP) deficiency].
Sakiyama T
Nihon Rinsho; 1996 Dec; 54(12):3328-32. PubMed ID: 8976114
[TBL] [Abstract][Full Text] [Related]
14. beta-galactosidase transduced T lymphocytes: a comparison between stimulation by either PHA and IL-2 or a mixed lymphocyte reaction.
Di Ianni M; Casciari C; Ciurnelli R; Fulvi A; Bagnis C; Lucheroni F; Falzetti F; Mannoni P; Martelli MF; Tabilio A
Haematologica; 1996; 81(5):410-7. PubMed ID: 8952153
[TBL] [Abstract][Full Text] [Related]
15. Potent orally bioavailable purine nucleoside phosphorylase inhibitor BCX-4208 induces apoptosis in B- and T-lymphocytes--a novel treatment approach for autoimmune diseases, organ transplantation and hematologic malignancies.
Bantia S; Parker C; Upshaw R; Cunningham A; Kotian P; Kilpatrick JM; Morris P; Chand P; Babu YS
Int Immunopharmacol; 2010 Jul; 10(7):784-90. PubMed ID: 20399911
[TBL] [Abstract][Full Text] [Related]
16. Purine nucleoside phosphorylase inhibitors in T-cell malignancies.
Bantia S; Kilpatrick JM
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):243-7. PubMed ID: 15603259
[TBL] [Abstract][Full Text] [Related]
17. Lymphoid development and function in X-linked severe combined immunodeficiency mice after stem cell gene therapy.
Otsu M; Anderson SM; Bodine DM; Puck JM; O'Shea JJ; Candotti F
Mol Ther; 2000 Feb; 1(2):145-53. PubMed ID: 10933924
[TBL] [Abstract][Full Text] [Related]
18. Retrovirus-mediated transfer of the human alpha-L-iduronidase cDNA into human hematopoietic progenitor cells leads to correction in trans of Hurler fibroblasts.
Huang MM; Wong A; Yu X; Kakkis E; Kohn DB
Gene Ther; 1997 Nov; 4(11):1150-9. PubMed ID: 9425437
[TBL] [Abstract][Full Text] [Related]
19. Retroviral transduction of protein kinase C-gamma into tumor-specific T cells allows antigen-independent long-term growth in IL-2 with retention of functional specificity in vitro and ability to mediate tumor therapy in vivo.
Chen W; Schweins E; Chen X; Finn OJ; Cheever MA
J Immunol; 1994 Oct; 153(8):3630-8. PubMed ID: 7930583
[TBL] [Abstract][Full Text] [Related]
20. EdU incorporation is an alternative non-radioactive assay to [(3)H]thymidine uptake for in vitro measurement of mice T-cell proliferations.
Yu Y; Arora A; Min W; Roifman CM; Grunebaum E
J Immunol Methods; 2009 Oct; 350(1-2):29-35. PubMed ID: 19647746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
